FULC · Categories · Form 4

FULC - SEC Form 4 insider transactions

Fulcrum Therapeutics Inc. (FULC) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.

Recent Form 4 for FULC

• 85d
  Amendment: Director Gould Robert J sold $163,089 worth of shares (15,000 units at $10.87), decreasing direct ownership by 3% to 469,864 units (SEC Form 4)

  4/A - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 85d
  SEC Form 4 filed by Chief Financial Officer Musso Alan A

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 85d
  SEC Form 4 filed by Principal Accounting Officer Tourangeau Greg

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 85d
  SEC Form 4 filed by Chief Legal Officer Oltmans Curtis Gale

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 85d
  Director Gould Robert J sold $160,857 worth of shares (15,000 units at $10.72), decreasing direct ownership by 3% to 454,864 units (SEC Form 4)

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 85d
  SEC Form 4 filed by Officer Sapir Alex

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 114d
  Director Gould Robert J sold $178,089 worth of shares (15,000 units at $11.87), decreasing direct ownership by 3% to 469,864 units (SEC Form 4)

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 134d
  Chief Legal Officer Oltmans Curtis Gale sold $44,600 worth of shares (3,452 units at $12.92), decreasing direct ownership by 25% to 10,252 units (SEC Form 4)

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 141d
  Large owner Ra Capital Management, L.P. sold $58,377,021 worth of shares (4,175,139 units at $13.98) (SEC Form 4)

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 160d
  Director Gould Robert J sold $165,495 worth of shares (15,000 units at $11.03), decreasing direct ownership by 3% to 484,864 units (SEC Form 4)

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 304d
  SEC Form 4 filed by Director Hill Colin

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 304d
  SEC Form 4 filed by Director Ezekowitz Alan

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 304d
  SEC Form 4 filed by Director Haviland Kate

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 304d
  SEC Form 4 filed by Director Dorton Katina

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 304d
  SEC Form 4 filed by Director Geraghty James A

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 304d
  SEC Form 4 filed by Director King Rachel K.

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 304d
  SEC Form 4 filed by Director Gould Robert J

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 304d
  SEC Form 4 filed by Director Banks Sonja

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 356d
  Principal Accounting Officer Tourangeau Greg sold $2,520 worth of shares (498 units at $5.06), decreasing direct ownership by 3% to 14,062 units (SEC Form 4)

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 457d
  SEC Form 4 filed by Chief Financial Officer Musso Alan A

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 457d
  SEC Form 4 filed by Chief Legal Officer Oltmans Curtis Gale

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 457d
  SEC Form 4 filed by Officer Sapir Alex

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 457d
  SEC Form 4 filed by Principal Accounting Officer Tourangeau Greg

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 532d
  SEC Form 4 filed by Director King Rachel K.

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 615d
  Large owner Ra Capital Management, L.P. disposed of 8,500,000 shares (SEC Form 4)

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 661d
  Officer Sapir Alex exercised 150,000 shares at a strike of $3.27, increasing direct ownership by 346% to 193,360 units (SEC Form 4)

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 681d
  SEC Form 4 filed by Director Ezekowitz Alan

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 681d
  SEC Form 4 filed by Director Gould Robert J

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 681d
  SEC Form 4 filed by Director Haviland Kate

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 681d
  SEC Form 4 filed by Director Banks Sonja

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 681d
  SEC Form 4 filed by Director Collins James J.

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 681d
  SEC Form 4 filed by Director Dorton Katina

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 681d
  SEC Form 4 filed by Director Geraghty James A

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 681d
  SEC Form 4 filed by Director Hill Colin

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 721d
  Tourangeau Greg sold $1,831 worth of shares (236 units at $7.76), decreasing direct ownership by 2% to 11,571 units (SEC Form 4)

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 771d
  SEC Form 4 filed by Horn Patrick Taylor

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 783d
  Tourangeau Greg sold $57,219 worth of shares (4,884 units at $11.72), decreasing direct ownership by 29% to 11,807 units (SEC Form 4)

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 821d
  SEC Form 4 filed by Tourangeau Greg

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 821d
  SEC Form 4 filed by Musso Alan A

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 821d
  SEC Form 4 filed by Oltmans Curtis Gale

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 832d
  SEC Form 4 filed by Musso Alan A

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 995d
  SEC Form 4 filed by Musso Alan A

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 1036d
  SEC Form 4 filed by Geraghty James A

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 1036d
  SEC Form 4 filed by Dorton Katina

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 1036d
  SEC Form 4 filed by Banks Sonja

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 1036d
  SEC Form 4 filed by Haviland Kate

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 1036d
  SEC Form 4 filed by Ezekowitz Alan

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 1036d
  SEC Form 4 filed by Gould Robert J

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 1036d
  SEC Form 4 filed by Collins James J.

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 1085d
  SEC Form 4 filed by Tourangeau Greg

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 1098d
  SEC Form 4 filed by Hayes Melvin H. Iii

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 1098d
  SEC Form 4 filed by Oltmans Curtis Gale

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 1172d
  SEC Form 4 filed by Oltmans Curtis Gale

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 1172d
  SEC Form 4 filed by Tourangeau Greg

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 1172d
  SEC Form 4 filed by Hayes Melvin H. Iii

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 1172d
  SEC Form 4 filed by Rajavelu Esther

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 1192d
  SEC Form 4: Ra Capital Management, L.P. bought $24,999,988 worth of shares (1,923,076 units at $13.00)

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 1203d
  SEC Form 4: Gould Robert J sold $101,490 worth of shares (6,766 units at $15.00) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 499,864 units

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 1210d
  SEC Form 4: Ra Capital Management, L.P. bought $1,314,806 worth of shares (180,703 units at $7.28)

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 1218d
  SEC Form 4: Ra Capital Management, L.P. bought $24,510 worth of shares (4,089 units at $5.99)

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)

Other FULC categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings
• Dividends